Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design. - Wikidata - wikimedia - TriplyDB

Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design.

Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design.

http://www.wikidata.org/entity/Q39935569

about

Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications Long-term survival and PSA control with radiation and immunotherapy for node positive prostate cancer Vaccines as monotherapy and in combination therapy for prostate cancer.Impact of tumour volume on the potential efficacy of therapeutic vaccines.Therapeutic cancer vaccines: current status and moving forward.Clinical evaluation of TRICOM vector therapeutic cancer vaccines Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer.Multidimensional glycan arrays for enhanced antibody profiling From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research.Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies.Immunotherapy in prostate cancer: emerging strategies against a formidable foe.Ganoderic Acid DM: An Alternative Agent for the Treatment of Advanced Prostate Cancer.Novel targeted agents on the horizon for castration-resistant prostate cancer.Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer.

P2860

Q27008070-35B54F50-2C03-4346-9C69-E0FB570F92D9 Q33621393-7D0BCC4A-422D-4E95-A883-97790E4F55A7 Q33712858-5CCA40D6-2A40-40C9-9A39-7BD2B0DF05D4 Q34039068-C824BF7A-CB0E-4823-878C-1E1F6969BFA0 Q35027034-E1200AEB-2D74-46A0-822A-5067ACF86A16 Q35894347-4480A3B0-7802-493E-98F0-35127E422F37 Q36099965-32756A6D-2E78-4784-BB88-46F5D01A3BB4 Q36285594-597CB06F-759E-43EE-AFA3-676D6C226C44 Q36291980-97F26DB8-B476-4E13-86FF-1A753E96F20B Q36293995-4218D1E6-7826-473B-AA00-AB3D0AABF7A6 Q36316871-AF9FC49F-4DA9-44F6-950A-A14A5F59ED2B Q36567448-3C61BB35-0458-4EA8-951B-95B6E1C3548E Q36708792-5B94ECD4-9FBC-498D-AD56-740F5AFF62C8 Q37727746-83DDCBEA-D7F1-4855-B5F7-80A91FD8DC89 Q37818294-5B12D840-87C1-43CD-842D-E8B3B213DA46 Q40241848-7D5FD924-0A53-4BBD-B304-E780DED47D96

P2860

Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design.

http://www.wikidata.org/entity/Q39935569

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Therapeutic vaccines in metast ...... ples in clinical trial design.

@en

Therapeutic vaccines in metast ...... ples in clinical trial design.

@nl

type

label

Therapeutic vaccines in metast ...... ples in clinical trial design.

@en

Therapeutic vaccines in metast ...... ples in clinical trial design.

@nl

prefLabel

Therapeutic vaccines in metast ...... ples in clinical trial design.

@en

Therapeutic vaccines in metast ...... ples in clinical trial design.

@nl

P1433

Q39935569-656C9F3E-9AE7-4B31-BFD8-4594D7EA4E9F

P1476

Q39935569-9021D99C-5659-4A8E-AA78-BF57D991AA5E

P2093

Q39935569-3F728513-9025-49CE-AEC6-FEC263694DAC

Q39935569-89EC1A84-8DED-4402-8744-8E4472F11466

Q39935569-AAB4D4EA-5F82-4C47-A0DD-A5CD54F97631

Q39935569-BF98A572-168A-4678-8DC5-F69B82233BAE

P2860

Q39935569-033AD88B-3FFA-4708-8D5B-5FEBCEEDBE85

Q39935569-0628F831-5663-401C-8E63-D32599B7C86F

Q39935569-0762884F-76F0-4E92-9E9C-8BF47231634F

Q39935569-0D58C5BA-4D60-4387-BF00-5A5471832316

Q39935569-12621583-EAF4-49EE-96E1-98A1B2C7554D

Q39935569-1311B36A-5149-40D0-99D0-6DF95BAF1573

Q39935569-17C5E58B-021B-4993-AA9F-CA4E3DAFDC3F

Q39935569-1EB46867-6084-4E13-9DB4-CD0B1432732B

Q39935569-2ED65785-098E-4A6F-B010-34B89F37A6AD

Q39935569-337B254F-FD86-434D-AC07-8E7A7F65B1A5

P304

Q39935569-AA28A59C-AEE8-4B0C-B756-E29FCB4524EB

P31

Q39935569-C9719B42-4F36-4492-9F33-E14D6BCDB7B4

P356

Q39935569-5309F80E-F75E-4917-9E74-0889ADD347EA

P407

Q39935569-BEBD8903-FF38-4256-A1E2-FB1A3EAFC391

P433

Q39935569-7C99299D-E86C-462C-875B-290F01B0CBFB

P478

Q39935569-394933FC-7A56-44DA-8EE4-A35BCE54DB9D

P577

Q39935569-B62203EB-0C2C-405C-8A29-DB1881614E0F

P698

Q39935569-690947B7-8A92-4BAE-8A61-C924F363A9F6

P932

Q39935569-950D1AD0-8A21-44A4-8E64-11B822ABC36D

P356

14712590903321421

P1433

Expert Opinion on Biological Therapy

P1476

Therapeutic vaccines in metast ...... iples in clinical trial design

@en

P2093

James L Gulley

http://www.w3.org/2001/XMLSchema#string

Jeffrey Schlom

http://www.w3.org/2001/XMLSchema#string

Mahsa Mohebtash

http://www.w3.org/2001/XMLSchema#string

Ravi A Madan

http://www.w3.org/2001/XMLSchema#string

P2860

NGEP, a gene encoding a membrane protein detected only in prostate cancer and normal prostate

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Molecular cloning and sequence analysis of cDNA encoding human prostatic acid phosphatase

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer.

P304

19-28

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712590903321421

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19857185

http://www.w3.org/2001/XMLSchema#string

P932

6628898

http://www.w3.org/2001/XMLSchema#string